These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31955626)

  • 21. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
    Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y
    Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
    Nishimura N; Kitade M; Noguchi R; Namisaki T; Moriya K; Takeda K; Okura Y; Aihara Y; Douhara A; Kawaratani H; Asada K; Yoshiji H
    J Gastroenterol; 2016 Dec; 51(12):1141-1149. PubMed ID: 27025708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipragliflozin: first global approval.
    Poole RM; Dungo RT
    Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
    Takasu T; Takakura S
    Biol Pharm Bull; 2018; 41(5):761-769. PubMed ID: 29709913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
    Tahara A
    Eur J Pharmacol; 2021 Nov; 910():174486. PubMed ID: 34487707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
    Hosokawa K; Takata T; Sugihara T; Matono T; Koda M; Kanda T; Taniguchi S; Ida A; Mae Y; Yamamoto M; Iyama T; Fukuda S; Isomoto H
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31888083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
    Takasu T; Yokono M; Tahara A; Takakura S
    Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
    Takeda A; Irahara A; Nakano A; Takata E; Koketsu Y; Kimata K; Senda E; Yamada H; Ichikawa K; Fujimori T; Sumida Y
    Intern Med; 2017 Oct; 56(20):2739-2744. PubMed ID: 28924123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
    Koike M; Saito H; Kohno G; Takubo M; Watanabe K; Ishihara H
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
    Takakura S; Toyoshi T; Hayashizaki Y; Takasu T
    Life Sci; 2016 Feb; 147():125-31. PubMed ID: 26829386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
    Toyoshima J; Saito M; Kaibara A; Isaka H; Sakatani T
    Clin Ther; 2020 Sep; 42(9):1787-1798.e3. PubMed ID: 32839028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
    Wang H; Yao G; Chen X; Ouyang J; Yang J
    Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
    Takasu T; Takakura S
    Life Sci; 2019 Aug; 230():19-27. PubMed ID: 31125563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
    Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
    FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
    Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
    Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishikawa T; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Tatsuno I; Terano T; Hashimoto N; Kuribayashi N; Uchida D; Yokote K;
    BMJ Open; 2017 May; 7(5):e015766. PubMed ID: 28490565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
    Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
    Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Kayama Y; Takeda N; Minamisawa S; Utsunomiya K
    Sci Rep; 2017 Sep; 7(1):11906. PubMed ID: 28928461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
    Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
    Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.